Table 1.
Available immune checkpoint inhibitors and indications.
| Drug (brand name) First approval |
Type of cancer |
|---|---|
| Ipilimumab (Yervoy) Mar 2011 |
Unresectable or metastatic melanoma in adult and juvenile (≥12 years) patients; melanoma stage III after complete resection as adjuvant therapy. |
| Nivolumab (Opdivo) Dec 2014 |
Unresectable or metastatic melanoma as monotherapy or in combination with ipilimumab; Melanoma stage III-IV after complete resection as adjuvant therapy; Metastatic NSCLC refractory to platinum-based CTX; Renal cell carcinoma as monotherapy or in combination with ipilimumab; Relapsed classical Hodgkin lymphoma after HSCT and ≥ 3 lines of therapy; Recurrent or metastatic HNSCC with progression after CTX; Microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer with progression after CTX. |
| Pembrolizumab (Keytruda) Sep 2014 |
Unresectable or metastatic melanoma; Metastatic NSCLC with high PDL1 expression or progression after CTX; Recurrent or metastatic HNSCC with progression after CTX; Relapsed classical Hodgkin lymphoma; Advanced or metastatic urothelial carcinoma; Microsatellite instability-high or mismatch repair deficient tumors and no satisfactory alternative; Recurrent local or metastatic gastric cancer with expression of PDL1; Recurrent or metastatic cervical cancer with PDL1 expression and progression after CTX |
| Atezolizumab (Tecentriq) May 2016 |
Advanced or metastatic urothelial carcinoma not not suitable for CTX and/or PDL1 expression; Metastatic NSCLC refractory to platinum-based CTX. |
| Avelumab (Bavencio) Mar 2017 |
Metastatic Merkel cell carcinoma; Advanced or metastatic urothelial carcinoma with progression after CTX. |
| Durvalumab (Imfinzi) May 2017 |
Advanced or metastatic urothelial carcinoma with progression after CTX; NSCLC stage III with stable disease or remission following CTX and radiotherapy. |